Status:
COMPLETED
Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Congestive Heart Failure
Type II Diabetes Mellitus
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
This study will assess the effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure (NYHA Class I-III). Effect on HbA1c and overall safety and ...
Eligibility Criteria
Inclusion
- Patients with T2DM, diagnosed at least 3 months prior to Visit 1
- CHF (NYHA Class I, Class II, or Class III) at Visit 1
- LVEF \< 40%
Exclusion
- Pregnant or lactating female
- FPG ≥ 270 mg/dL (≥15 mmol/L)
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
798 Patients enrolled
Trial Details
Trial ID
NCT00894868
Start Date
May 1 2009
End Date
August 1 2012
Last Update
December 17 2020
Active Locations (93)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Benešov, Czech Republic, Czechia, 25601
2
Novartis Investigative Site
Havířov, Czech Republic, Czechia, 736 01
3
Novartis Investigative Site
Litomyšl, Czech Republic, Czechia, 570 14
4
Novartis Investigative Site
Prague, Czech Republic, Czechia, 140 00